U.S. Water Utilities Stock News

In recent days, Centessa Pharmaceuticals reported new preclinical data showing its selective OX2R agonist reduced behavioral despair and improved wakefulness in animal models of major depressive disorder, while also outlining plans to broaden its orexin pipeline across neuropsychiatric conditions with high unmet need. Coupled with strong analyst support, leadership changes, and a planned US$250,000,000 public offering to fund late-stage trials, these developments highlight how Centessa is...

In recent weeks, Levi Strauss & Co. has launched its Levi’s Wear Longer Project with Discovery Education, advanced AI and cloud retail tools with Microsoft, and prepared to report its fiscal 2025 results on a January 28, 2026 earnings call led by CEO Michelle Gass and CFO Harmit Singh. These moves, alongside recognition as the top retail apparel brand for customer loyalty and ongoing discounting of flagship 501 jeans, highlight how Levi’s is pairing brand-building sustainability efforts with...

Otter Tail (OTTR) just approved a higher quarterly dividend of $0.5775 per share, lifting the indicated annual payout to $2.31 and extending its dividend track record into an 88th consecutive year. See our latest analysis for Otter Tail. At a share price of $87.85, Otter Tail has logged a 6.98% 1 month share price return and 13.11% 3 month share price return, while its 5 year total shareholder return of 139.86% points to strong long term compounding alongside the newly higher dividend. If...

Recent commentary around St. Joe (JOE) has zeroed in on its exposure to internal migration into Florida’s panhandle, along with ongoing share buybacks and a dividend increase that together are drawing fresh attention from investors. See our latest analysis for St. Joe. At a share price of US$65.39, St. Joe’s recent 30-day share price return of 6.67% and 90-day gain of 33.97% suggest momentum has been building, while its 1-year total shareholder return of 37.44% points to solid longer term...

Analyst optimism lifts PennyMac Financial Services (PFSI) Several investment firms raised their outlook on PennyMac Financial Services (PFSI), citing a more supportive mortgage backdrop related to government housing policies and potential changes in interest rates. See our latest analysis for PennyMac Financial Services. PennyMac Financial Services' share price has climbed to $159.46, with a 5.81% 1 day share price return and a 31.35% 90 day share price return. Its 1 year total shareholder...

Recently, several research firms expressed increased confidence in ATI, citing stronger aerospace and defense order activity and ongoing strength in jet engine and maintenance markets, alongside leadership changes including a new Chief Financial Officer effective January 2026 and the current CEO’s planned transition to Board Chair in May 2026. The concentration of analyst optimism around ATI’s aerospace and defense exposure highlights how improving OEM demand and a tight aftermarket are...

Recently, LexinFintech Holdings was featured in research on promising penny stocks, highlighting its strong financial health rating and position within China's consumer finance sector. An interesting angle from this coverage is that LexinFintech is being framed as a lower-priced entry point where fundamentals, rather than speculation, are the primary focus for investors. Against this backdrop of attention on LexinFintech’s financial strength, we’ll examine how this recognition may influence...

Updated guidance puts Xeris Biopharma Holdings (XERS) on investors’ radar Xeris Biopharma Holdings (XERS) lifted its full-year 2025 revenue outlook, now guiding to approximately US$292 million, above the prior US$285 million to US$290 million range. This is a shift that directly affects how investors may view the stock. See our latest analysis for Xeris Biopharma Holdings. The updated revenue outlook arrives after a mixed price run, with a 1-day share price return of 1.48% and a 90-day share...

Recent analyst moves around First BanCorp (FBP) are in focus after Piper Sandler initiated coverage with a Neutral rating, and the bank reported quarterly adjusted EPS above expectations but revenue below forecasts. See our latest analysis for First BanCorp. The recent analyst updates and earnings release sit against a share price that has eased slightly over the past month but still carries a 1-year total shareholder return of 11.93% and a 5-year total shareholder return of 149.60%. This...

In January 2026, Polestar Automotive Holding UK PLC reported fourth-quarter 2025 retail sales of 15,608 cars and full-year sales of 60,119, both higher than the prior year. This step-up in retail volumes suggests that Polestar is managing to increase customer deliveries even as competition in the global EV market intensifies. We will now examine how this acceleration in full-year retail sales intersects with concerns about cash burn, competition, and Polestar’s longer-term investment...

In mid-January 2026, The J.M. Smucker Co. announced its Board approved a US$1.10 per share quarterly dividend, payable on March 2, 2026, to shareholders of record as of February 13, reinforcing its ongoing capital return to investors. Around the same time, Morgan Stanley cut its rating on J.M. Smucker to Equal Weight, underscoring concerns about rising competitive pressures and valuation risks despite the steady dividend payout. With Morgan Stanley flagging increased competitive risk, we’ll...

Legend Biotech (LEGN) used its recent J.P. Morgan conference update to spotlight revenue growth, margin progress and an outlook for profitability in 2026, anchored by its multiple myeloma therapy CARVYKTI and partnership with Johnson & Johnson. See our latest analysis for Legend Biotech. Legend Biotech’s recent conference update comes after a tough run for investors, with a 90 day share price return of a 32.73% decline and a 1 year total shareholder return of a 32.21% decline, while the 30...

In December, Immunome, Inc. reported positive topline results from its Phase 3 RINGSIDE trial, showing Varegacestat improved progression-free survival versus placebo and plans to seek FDA approval in the second quarter of 2026. The data, including a marked reduction in the risk of death or disease progression and a high rate of tumor shrinkage, positions Varegacestat as a potentially important addition to Immunome’s oncology pipeline. Next, we’ll examine how Varegacestat’s strong Phase 3...

Fortrea Holdings (FTRE) saw its shares climb 4.8% after Evercore ISI upgraded the stock, citing stronger than expected revenue and profit margins, progress on debt reduction, and a quickening biopharma cycle. See our latest analysis for Fortrea Holdings. Even after the upgrade driven jump, Fortrea’s recent trading has been choppy. The 1 day share price return of 3.38% contrasts with 7 day and 30 day share price returns of 5.12% and 6.99% declines. A 90 day share price return of 58.35% hints...

What the recent return profile says about Post Holdings stock Post Holdings (POST) shares have tracked a mixed path recently, with a 1 day gain of about 1.3%, modest movement over the past week, and declines over the month and past 3 months. Over longer periods, the picture shifts, with negative total return over the past year but positive outcomes over 3 and 5 years. This can matter if you are thinking about holding the stock through different market cycles. Alongside that performance...

IDEAYA Biosciences (IDYA) is back in focus after a cluster of upbeat analyst reports highlighted its precision oncology pipeline and its partnerships with GlaxoSmithKline, Pfizer, and Gilead, drawing fresh attention to the stock. See our latest analysis for IDEAYA Biosciences. After a strong run that leaves the 1 year total shareholder return at 61.59% and the 3 year total shareholder return just over double, recent 7 day and 1 day share price weakness sits against a 90 day share price return...

Prosperity Bancshares (PB) has been drawing attention after recent share price moves, with the stock closing at US$72.39 and showing mixed returns over the past year and the past 3 months. See our latest analysis for Prosperity Bancshares. The recent pullback in the 1-day share price return of 1% comes after a stronger 90-day share price return of 13.09%. At the same time, the 1-year total shareholder return shows a decline of 5.08%, indicating that longer term results have been more muted...

Asthma data and 2026 pipeline milestones come into focus Apogee Therapeutics (APGE) attracted fresh attention after reporting positive interim Phase 1b data for zumilokibart in mild to moderate asthma, alongside outlining key 2026 milestones across atopic dermatitis and other inflammatory indications. See our latest analysis for Apogee Therapeutics. Against this backdrop, Apogee’s recent asthma update and 2026 pipeline timeline arrive after a strong 90 day share price return of 41.85% and a 1...

In the recent quarter, Core & Main reported revenue growth of 1.2% year on year and delivered adjusted operating income above analyst expectations, signaling resilient demand across its water infrastructure distribution business. This earnings performance highlights how Core & Main’s focus on supply chain and inventory management is becoming a central driver of its operational strength within industrial distribution. With this earnings beat underscoring operational execution, we’ll now...

If you are wondering whether Under Armour’s current share price offers a genuine bargain or just appears cheap on the surface, this article is designed to walk you through the key valuation angles to consider. The stock last closed at US$5.78, with returns of 2.5% over 7 days, 27.6% over 30 days and 9.3% year to date, but a 29.5% decline over 1 year, a 50.5% decline over 3 years and a 68.8% decline over 5 years, which raises questions about how the market now views its potential and...

In the past few days, Allegion plc has prepared to release its fiscal Q4 2025 results, with analysts expecting an 8.1% year-on-year increase in earnings per share and pointing to a four-quarter streak of beating Wall Street forecasts. The consistently higher-than-expected earnings and current "Moderate Buy" analyst rating suggest investors are paying close attention to how Allegion executes on its access security growth plans. We’ll now examine how Allegion’s history of outperforming...

In January 2026, Delek US Holdings released a new investor presentation outlining its Enterprise Optimization Plan, expected cash flow enhancements, and capital allocation priorities, alongside benefits from recent EPA small refinery exemption relief that is projected to unlock US$400 million in cash and add US$200 million in annual cash flow. The company is also planning a major turnaround at its Big Spring refinery in early 2026 to improve reliability, optimize its crude slate, and enhance...

Wondering whether Lennar's current share price truly reflects its underlying value, or if the market is mispricing this homebuilder? This article is built to help you think that through clearly. Lennar's shares last closed at US$118.59, with a 30 day return of 9.8%, a year to date return of 13.8%, a 1 year return of a 7.8% decline, and longer term 3 year and 5 year returns of 38.6% and 63.0% respectively. Recent price moves sit against a backdrop of ongoing attention on US housing demand,...

If you are wondering whether Organon’s current share price reflects its underlying worth, you are not alone. This article focuses on how its market price compares with its estimated value. Organon’s stock last closed at US$8.76, with recent returns of 8.8% over 7 days, 28.3% over 30 days and 21.0% year to date, while the 1 year and 3 year returns stand at 42.9% and 67.6% declines. These moves come against a backdrop of ongoing attention on Organon’s role in the pharmaceuticals and biotech...